Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

BIOWEG secures €14M additional Series A funding to build Europe's largest bacterial cellulose plant in Elsdorf, Germany.

PRIVATESep 12, 2026•about 3 hours ago

Amount Raised

€14 Million

Round Type

Series A

QuakenbrueckBiotechnology

Investors

Rabo Ventures

Description

German deeptech company BIOWEG has secured €14 million in additional Series A funding, including €2 million in equity from Rabo Ventures, extending its Series A round to €18 million. The funding will support construction of Europe's largest bacterial cellulose production facility in Elsdorf, North Rhine-Westphalia, capable of producing 10,000 tons annually. Commercial production is expected to begin in 2028. BIOWEG's total funding, including €10.3 million in EU grants and €2 million from other sources, now reaches €35 million.

Company Information

Company

BIOWEG

Location

Quakenbrueck, Niedersachsen, Germany

About

BIOWEG, founded in 2019 in Germany, is a purpose-driven organization powered by conscious ChemDesign. We match Bio-innovation to business problems. We explore and combine biotechnology, material science, and molecular simulation learning to create advanced sustainable bio-based high-performance ingredients. Our ingredients are 100% animal free, globally scalable, and sustainably produced without harsh chemicals. We work with results-oriented, forward-thinking companies, and consumer brands with global scale in the cosmetics, personal care, nutraceuticals, agricultural coatings, and food/beverage sectors who desire highly differentiated and sustainable science-based ingredient technologies.

Don't miss BIOWEG's next move

Get an email the moment BIOWEG raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
2 contacts
Verified contactsNicolas B., Head of Sales
Predictive Intelligence
Strategic

ML-powered predictions for BIOWEG's next move

See what Strategic adds

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

BIOWEG raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.